跳至主要内容
临床试验/NCT01550640
NCT01550640已完成不适用

Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia

Charles University, Czech Republic1 个研究点 分布在 1 个国家目标入组 149 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
149
试验地点
1
主要终点
Newborn adaptation after delivery

研究概览

简要总结

Caesarean delivery under general anaesthesia (GA) carries nowadays still 25% risk of insufficient depth of anaesthesia in a time before the fetus delivery. The reason is the lack of opioid administration. Opioids easily cross placental barrier and negatively influence newborn postpartum adaptation by respiratory depression. Introduction to GA is thus accompanied by exaggerated autonomic stress reaction with hypertension and tachycardia. The use of ultra-short acting opioid remifentanil should suppress stress response in mother without increasing the risk for newborn. There are only a few clinical data available. This study will be the first one systematically studying the influence of remifentanil in pregnant women with hypertension on hemodynamic stability and newborns safety. This study will also identify potential pharmacogenetic factors of individual variability in remifentanil response with respect of drug efficacy and safety in mother and newborn.

详细描述

INTRODUCTION Even nowadays there is still a significant risk of insufficient depth of anesthesia during Cesarean delivery (CD) under general anesthesia (GA). The main reason in comparison to other surgeries is the lack of opioid administration due to risk of newborn respiratory depression.

Opioids easily cross the placental barrier to the fetus circulation and may cause depression of respiration and deteriorate the overall newborns postpartum adaptation. This presents the main reason why according to contemporary recommendation is the use of opioids in CD restricted until the time of fetus delivery, and are given as far as after the navel wort ligation. Not to cause any depression of the newborn the premedication to GA is usually also omitted. The beginning of GA in common surgical operation is usually accompanied by the decrease in systemic blood pressure (BP) and heart rate (HR). However, in CD the investigators face the increase of BP and HR due to stress reaction of mother during the period before the fetus delivery and before full anesthesia application, including opioids.

Generally, insufficient depth of anesthesia (assessed by patient's recollection) is reported in less than 1% of cases, but increases for up to 50% in GA during CD. However, this appraisal marginalized much more frequent cases when an insufficient depth of GA is accompanied by exaggerated autonomic reaction to the pain, especially the increase in systemic BP and heart rate as a reaction to the egestion of catecholamines, while total amnesia of the surgery is retained. In CD such type of anesthesia insufficiency was reported in 12-26% of patients! Current trend in CD anesthesia unequivocally prefers the use of regional techniques; GA remains indicated for emergency situations mainly and in those cases the stress reaction of mother tends to be much higher than in elective procedures.

An independent remarkable risk factor to the pregnant women is the hypertension, both chronic and gestational including preeclampsia. This condition of preoperatively mostly hardly and insufficiently controlled hypertension may get dramatically worse during the first phase of CD, when blood pressure due to uncontrolled stress reaction enormously rises and elevates intracranial pressure with high risk of hemorrhagic stroke - a life threatening complication.

Unfortunately there are only a few possibilities how to influence mother's stress response to intubation and laparotomy without increasing the risk of newborn depression. In absence of anesthetics not crossing placental barrier, the only possibility is the use of ultra-short acting anesthetics which should be eliminated from fetus circulation before his delivery. An important role might play remifentanil - µ-receptor agonist with rapid onset and ultra-short activity (biological half-life 3-10 min.). It's major advantage, beside fast onset, is also prompt and organs independent elimination.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women,
  • age 18-45
  • Cesarean delivery under general anesthesia
  • informed consent

排除标准

  • non-cooperative patient
  • previous allergy to remifentanil or additional substance
  • multiparity
  • age of foetus <35th week
  • estimated foetus weight <2500 g
  • hypoxia or other signs of foetus distress
  • mother's hypotension
  • Discontinuation Criteria:
  • difficult foetus delivery (uterine incision-to-delivery interval >3 min)

研究组 & 干预措施

remifentanil

Experimental

bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia

干预措施: Remifentanil (Drug)

结局指标

主要结局

Newborn adaptation after delivery

时间窗: 10 min after delivery

newborn status (Apgar score + acid-base measurement from umbilical cord, clinical evaluation and scoring)

Influence of individual hereditary variability in MDR1 (multidrug resistance gene 1) and PXR (pregnane X receptor) on remifentanil pharmacodynamics.

时间窗: at time of delivery

次要结局

  • Depth of anesthesia(30 min from induction to general anesthesia)
  • Hemodynamic response to intubation and beginning of Cesarean operation(30 min from induction to general anesthesia)

研究者

发起方
Charles University, Czech Republic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jan Blaha, MD, PhD.

Principal Investigator

Charles University, Czech Republic

研究点 (1)

Loading locations...

相似试验